查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612883

導管相關血流感染市場：按藥物類別、給藥途徑、適應症、分銷管道分類 - 全球預測 2025-2030 年

Catheter-related Bloodstream Infections Market by Drug Class (Cefazoline, Ceftazidime, Cloxacillin), Route of Administration (Injectable, Oral), Indication, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年導管相關血流感染市場價值為16.4億美元，預計2024年將達到17.4億美元，複合年成長率為5.88%，2030年將達24.6億美元。

導管相關血流感染 (CRBSI) 是醫療機構中的一個重大問題，需要持續的市場研究來尋找預防和治療解決方案。 CRBSI 的範圍包括確定感染源、制定預防策略和加強治療通訊協定，影響尋求最大限度降低感染率的醫院和醫療保健提供者。由於導管相關手術的數量不斷增加以及加護病房患者的脆弱性日益增加，該市場變得極為重要。主要應用包括使用先進的抗菌導管、塗層和鎖定解決方案來降低感染率。最終用途主要包括醫院、專科診所和門診病人中心。導管設計和塗層技術的進步提高了安全性，以及需要導管治療的慢性疾病的盛行率不斷增加，推動了市場成長。

主要市場統計
基準年[2023] 16.4億美元
預計年份 [2024] 17.4億美元
預測年份 [2030] 24.6億美元
複合年成長率（%） 5.88%

關鍵的成長要素包括感染控制意識的提高和更嚴格的監管指南。隨著政府衛生支出的增加和私人研發投資的增加，有開發具有成本效益且高效的預防措施和治療方法的重大機會。然而，他們也面臨挑戰，例如先進醫療設備的高成本、潛在的副作用以及創新解決方案研發的複雜性。最新的潛在商機圍繞著人工智慧和機器學習的整合，用於感染風險的預測分析，以及開發用於即時監測 CRBSI 的下一代生物感測器。

為了持續成長，公司應專注於與醫療機構的合作，進行試驗計畫來測試新技術，並收集真實的有效性資料。此外，探索研究經費和創新津貼的夥伴關係可以進一步加速市場採用。然而，報銷問題和複雜的監管途徑等限制可能會阻礙快速發展。特別是在全球永續性趨勢下，生物相容性和環保導管材料的創新是推動產業進步和市場滲透的一個有前景的研究領域。 CRBSI 市場充滿挑戰，但對於那些能夠駕馭其複雜性並投資前瞻性解決方案的公司來說充滿了機會。

市場動態：快速發展的導管相關血流感染市場的關鍵市場洞察

供需的動態交互作用正在改變導管相關的血流感染市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 人們越來越關注靜脈內細菌感染以及對有效治療方案的需求
    • 提高對導管相關血流的認知宣傳活動
  • 市場限制因素
    • 關於藥品核准和產品召回案例的嚴格政府法規
  • 市場機會
    • 政府針對細菌性行為感染的有利措施和政策
    • 開發新藥的藥物傳遞和研發活動的進展
  • 市場挑戰
    • 導管相關的血流感染過敏原和與藥物相關的嚴重健康問題

波特五力：駕馭導管相關血流感染市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解導管相關血流感染市場的外部影響

外部宏觀環境因素在塑造導管相關血流感染市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解導管相關血流感染市場的競爭狀況

對導管相關血流感染市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣導管相關血流感染市場供應商的績效評估

FPNV定位矩陣是評估導管相關血流感染市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，繪製導管相關血流感染市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對導管相關血流感染市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 對靜脈細菌感染疾病的日益關注以及對有效治療方法的需求
      • 提高對導管相關血流的認知宣傳活動
    • 抑制因素
      • 有關藥品核准和產品召回的嚴格政府法規
    • 機會
      • 首選政府針對細菌感染疾病的措施和政策
      • 持續進行研究和開發活動，以推動藥物輸送和開發新藥的進步
    • 任務
      • 導管相關的血流感染過敏原和與藥物相關的嚴重健康問題
  • 市場區隔分析
    • 藥物類別：廣泛使用Cefazolin和氯唑西林藥物治療導管引起的細菌感染疾病
    • 適應症：人們對有效管理以及預防和治療病毒和寄生蟲感染疾病的興趣日益濃厚
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類別分類的導管相關血流感染市場

  • Cefazolin
  • 頭孢他齊健身房
  • 氯唑西林
  • Daptomycin
  • Echinocandins
  • Teicoplanin
  • 萬古黴素

第7章導管相關血流感染市場：依給藥途徑

  • 可注射的
  • 口服

第8章導管相關血流感染市場（按適應症）

  • 細菌感染疾病
  • 黴菌感染疾病
  • 病毒和寄生蟲感染疾病

第9章導管相關血流感染市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章美洲導管相關血流感染市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區導管相關血流感染市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲導管相關血流感染市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Citius Pharmaceuticals 宣布完成 Mino-Lok 用於緩解感染導管的 3 期研究的招募
    • BD 與 Bactiguard 合作，增強全球感染預防Foley導管的可及性
    • FDA核准DefenCath 是預防血液透析機病人導管相關血流感染的重要一步。
  • 戰略分析和建議

公司名單

  • Advacare Pharma
  • AstraZeneca PLC
  • Bactiguard AB
  • Becton, Dickinson and Company
  • CorMedix Inc
  • Fresenius Medical Care AG
  • Glenmark Pharmaceuticals Ltd.
  • IntegraDose Compounding Services, LLC
  • Johnson & Johnson Services, Inc
  • JoinHub Pharma
  • Lupin Ltd.
  • Lyka Hetero Healthcare Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • TauroPhar GmbH
  • Xellia Pharmaceuticals Ltd.
Product Code: MRR-5D693B46C67B

The Catheter-related Bloodstream Infections Market was valued at USD 1.64 billion in 2023, expected to reach USD 1.74 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 2.46 billion by 2030.

Catheter-related bloodstream infections (CRBSIs) represent a significant concern in healthcare settings, necessitating ongoing market research into preventive and therapeutic solutions. The scope of CRBSI involves identifying sources, developing preventive strategies, and enhancing treatment protocols, impacting hospitals and healthcare providers aiming to minimize infection rates. This market is crucial due to the rising number of catheter-related procedures and the increased vulnerability of patients in intensive care units. Key applications involve the utilization of advanced antimicrobial catheters, coatings, and lock solutions aimed at reducing infection incidence. End-use primarily spans hospitals, specialty clinics, and outpatient centers. Market growth is driven by technological advancements in catheter designs and coatings that offer improved safety, along with the increasing prevalence of chronic diseases necessitating catheterization.

KEY MARKET STATISTICS
Base Year [2023] USD 1.64 billion
Estimated Year [2024] USD 1.74 billion
Forecast Year [2030] USD 2.46 billion
CAGR (%) 5.88%

Key growth influencers include heightened awareness and stringent regulatory guidelines focusing on infection control. There is a substantial opportunity in developing cost-effective and efficient preventive measures and treatments, backed by increasing governmental healthcare expenditures and private investments in research and innovation. However, the market also faces challenges such as high costs associated with advanced medical devices, potential side effects, and the complex nature of R&D for innovative solutions. The latest potential opportunities revolve around the integration of AI and machine learning for predictive analysis in infection risk as well as the development of next-generation biosensors for real-time monitoring of CRBSIs.

For continued growth, businesses should focus on collaborations with healthcare facilities to implement pilot programs testing new technologies and gathering real-world efficacy data. Additionally, exploring partnerships for research funding and innovation grants could further propel market adoption. Nevertheless, limitations such as reimbursement issues and the intricate nature of navigating regulatory pathways could impede rapid development. Innovating in biocompatible and eco-friendly materials for catheters, particularly amid global sustainability trends, presents a promising research area to leverage industry advancement and market penetration. The CRBSI market, though challenging, remains ripe with opportunities for those able to navigate its complexities and invest in forward-thinking solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Catheter-related Bloodstream Infections Market

The Catheter-related Bloodstream Infections Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing concerns about intravenous bacterial infections and the need for effective treatment options
    • Growing number of educational campaigns for awareness of catheter-related bloodstream
  • Market Restraints
    • Strict government regulations related to drug approvals and cases of product recalls
  • Market Opportunities
    • Favorable government initiatives and policies for bacterial infectious diseases
    • Advancements in the drug delivery and ongoing R&D activities for the novel drug development
  • Market Challenges
    • Allergens and significant health concerns associated with catheter-related bloodstream infections medications

Porter's Five Forces: A Strategic Tool for Navigating the Catheter-related Bloodstream Infections Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Catheter-related Bloodstream Infections Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Catheter-related Bloodstream Infections Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Catheter-related Bloodstream Infections Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Catheter-related Bloodstream Infections Market

A detailed market share analysis in the Catheter-related Bloodstream Infections Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Catheter-related Bloodstream Infections Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Catheter-related Bloodstream Infections Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Catheter-related Bloodstream Infections Market

A strategic analysis of the Catheter-related Bloodstream Infections Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Catheter-related Bloodstream Infections Market, highlighting leading vendors and their innovative profiles. These include Advacare Pharma, AstraZeneca PLC, Bactiguard AB, Becton, Dickinson and Company, CorMedix Inc, Fresenius Medical Care AG, Glenmark Pharmaceuticals Ltd., IntegraDose Compounding Services, LLC, Johnson & Johnson Services, Inc, JoinHub Pharma, Lupin Ltd., Lyka Hetero Healthcare Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi SA, TauroPhar GmbH, and Xellia Pharmaceuticals Ltd..

Market Segmentation & Coverage

This research report categorizes the Catheter-related Bloodstream Infections Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Cefazoline, Ceftazidime, Cloxacillin, Daptomycin, Echinocandin, Teicoplanin, and Vancomycin.
  • Based on Route of Administration, market is studied across Injectable and Oral.
  • Based on Indication, market is studied across Bacterial Infections, Fungal Infection, and Viral & Parasitic Infections.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing concerns about intravenous bacterial infections and the need for effective treatment options
      • 5.1.1.2. Growing number of educational campaigns for awareness of catheter-related bloodstream
    • 5.1.2. Restraints
      • 5.1.2.1. Strict government regulations related to drug approvals and cases of product recalls
    • 5.1.3. Opportunities
      • 5.1.3.1. Favorable government initiatives and policies for bacterial infectious diseases
      • 5.1.3.2. Advancements in the drug delivery and ongoing R&D activities for the novel drug development
    • 5.1.4. Challenges
      • 5.1.4.1. Allergens and significant health concerns associated with catheter-related bloodstream infections medications
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Extensive utililzation of Cefazoline and Cloxacillin medication in the treatment of bacterial infections caused by catheter
    • 5.2.2. Indication: Growing focus on the effective management and the prevention and treatment of viral & parasitic infections
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Catheter-related Bloodstream Infections Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Cefazoline
  • 6.3. Ceftazidime
  • 6.4. Cloxacillin
  • 6.5. Daptomycin
  • 6.6. Echinocandin
  • 6.7. Teicoplanin
  • 6.8. Vancomycin

7. Catheter-related Bloodstream Infections Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. Catheter-related Bloodstream Infections Market, by Indication

  • 8.1. Introduction
  • 8.2. Bacterial Infections
  • 8.3. Fungal Infection
  • 8.4. Viral & Parasitic Infections

9. Catheter-related Bloodstream Infections Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Catheter-related Bloodstream Infections Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Catheter-related Bloodstream Infections Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Catheter-related Bloodstream Infections Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Citius Pharmaceuticals Announces Completion of Phase 3 Trial Enrollment for Mino-Lok, Aiming to Salvage Infected Catheters
    • 13.3.2. BD Partners with Bactiguard to Enhance Global Access to Infection-Preventing Foley Catheters
    • 13.3.3. FDA Approval of DefenCath Marks a Significant Step in Catheter-Related Bloodstream Infection Prevention for Hemodialysis Patients
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Advacare Pharma
  • 2. AstraZeneca PLC
  • 3. Bactiguard AB
  • 4. Becton, Dickinson and Company
  • 5. CorMedix Inc
  • 6. Fresenius Medical Care AG
  • 7. Glenmark Pharmaceuticals Ltd.
  • 8. IntegraDose Compounding Services, LLC
  • 9. Johnson & Johnson Services, Inc
  • 10. JoinHub Pharma
  • 11. Lupin Ltd.
  • 12. Lyka Hetero Healthcare Ltd.
  • 13. Merck & Co., Inc.
  • 14. Novartis AG
  • 15. Pfizer Inc.
  • 16. Sanofi SA
  • 17. TauroPhar GmbH
  • 18. Xellia Pharmaceuticals Ltd.

LIST OF FIGURES

  • FIGURE 1. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET RESEARCH PROCESS
  • FIGURE 2. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET DYNAMICS
  • TABLE 7. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CEFAZOLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CEFTAZIDIME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY CLOXACILLIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ECHINOCANDIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY TEICOPLANIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY VANCOMYCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY FUNGAL INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY VIRAL & PARASITIC INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. CATHETER-RELATED BLOODSTREAM INFECTIONS MARKET, FPNV POSITIONING MATRIX, 2023